Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Phapros TbkISX:PEHA +10.95%76 EV-to-EBIT is 8.30 as of Aug. 31, 2026, which is 34% below its 10-year median of 12.53. GuruFocus rates ISX:PEHA with a GF Score™ of 76/100 and a GF Value™ of Rp380.69 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 685 Drug Manufacturers companies, PT Phapros Tbk ranks better than 78.39% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
PT Phapros Tbk's Enterprise Value for the quarter that ended in Mar. 2026 was Rp810,676 Mil.
PT Phapros Tbk's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp102,742 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Phapros Tbk EV-to-EBIT Related Terms
PT Phapros Tbk EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for PT Phapros Tbk's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISX:PEHA vs ZTS, UTHR, VTRS: EV-to-EBIT Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PT Phapros Tbk's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Phapros Tbk EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PT Phapros Tbk's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where PT Phapros Tbk's EV-to-EBIT falls into.
PT Phapros Tbk's current Enterprise Value is Rp853,225 Mil.
PT Phapros Tbk's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp102,742 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Phapros Tbk (ISX:PEHA) has a EV-to-EBIT of 8.30 as of Aug. 31, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on PT Phapros Tbk and its competitors. This is 34% below median its historical median of 12.53. According to the industry distribution chart, PT Phapros Tbk ranks #148 out of 685 companies in the Drug Manufacturers industry, placing it in the top 21.6%.
Is PT Phapros Tbk's EV-to-EBIT too high?
PT Phapros Tbk's current EV-to-EBIT of 8.30 is 34% below median its 10-year median of 12.53. The Drug Manufacturers industry median EV-to-EBIT is 16.22. PT Phapros Tbk's value of 8.30 is 48.8% below this industry median. Based on the distribution chart, PT Phapros Tbk ranks #148 out of 685 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, PT Phapros Tbk has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Phapros Tbk's EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PT Phapros Tbk ranks #148 out of 685 companies for EV-to-EBIT. This places PT Phapros Tbk in the top 22% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 16.22. PT Phapros Tbk's value of 8.30 is 48.8% below this benchmark. While the company's 10-year median is 12.53 vs. the industry median of 16.22, PT Phapros Tbk has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 16.22, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Phapros Tbk's current EV-to-EBIT of 8.30 is 48.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on PT Phapros Tbk and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 16.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Phapros Tbk's current EV-to-EBIT is 8.30, which is 34% below median its own 10-year median of 12.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Phapros Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Phapros Tbk (ISX:PEHA) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp380.69, compared to a current price of Rp304.00 — trading 20.1% below its estimated fair value. The current EV-to-EBIT is 8.30, which is 34% below median its 10-year median of 12.53 and 48.8% below the Drug Manufacturers industry median of 16.22. PT Phapros Tbk's overall GF Score™ is 76/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For PT Phapros Tbk (ISX:PEHA), the current EV-to-EBIT is 8.30 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Phapros Tbk (ISX:PEHA) Overvalued in 2026?
Based on GuruFocus' analysis, PT Phapros Tbk stock appears to be undervalued.
The current stock price of Rp304.00 is trading 20.1% below its estimated GF Value™ of Rp380.69.
GuruFocus considers PT Phapros Tbk to be Modestly Undervalued.
Key valuation signals for ISX:PEHA:
EV-to-EBIT: 8.30 (34% below median its 10-year median of 12.53)
GF Value™: Rp380.69 vs. price of Rp304.00 (20.1% below fair value)
Industry Position: 48.8% below the Drug Manufacturers median (#148 of 685)
No single metric tells the full story. See the ISX:PEHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Phapros Tbk is a pharmaceutical company in Indonesia. The company is engaged in the industrial/manufacturing sector by producing and/or trading medicines, health instruments, chemical goods, and other similar goods in import, export, and other kinds of industry. The company operates through Over Counter (OTC), Ethical, Generic Drugs Bearing (OGB), and Toll Manufacturing segments. It derives maximum revenue from OGB segment.
76GF Score
Get the complete analysis for ISX:PEHA
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:PEHA has been successfully added to your 
